证券代码：688513 证券简称：苑东生物 公告编号：2025-076 成都苑东生物制药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 成都苑东生物制药股份有限公司（以下简称"公司"）即将于 2025 年 10 月 28 日披露公司 2025 年第三季度报告，为加强与投资者的深入交流，使投资者更加 全面、深入地了解公司 2025 年第三季度的经营成果、财务指标等情况，公司计 划于 2025 年 10 月 31 日（星期五）上午 11:00-12:00 举行 2025 年第三季度业绩 说明会，就投资者关心的问题进行交流。 1 会议召开时间：2025 年 10 月 31 日（星期五）上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 24 日（星 ...

华泰柏瑞价值增长混合A（460005）成立日期2008年7月16日，最新规模6.72亿。今年以来收益 40.63%，同类排名1503/8159；近一年收益42.89%，同类排名1127/8030；成立以来收益722.68%。 华泰柏瑞价值增长混合A（460005）基金经理为方纬。 截至发稿，方纬累计任职时间11年66天，现任基金资产总规模21.27亿元，任职期间最佳基金回报 260.51%， 任职期间最差基金回报-17.22%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 10月23日，苑东生物跌5.05%，截至发稿，报50.42元/股，成交4838.56万元，换手率0.53%，总市值 89.01亿元。 资料显示，成都苑东生物制药股份有限公司位于四川省成都市双流区安康路8号，成立日期2009年6月1 日，上市日期2020年9月2日，公司主营业务涉及化学原料药和化学药制剂的研发、生产与销售。主营业 务收入构成为：制剂销售78.75%，原料药销售9.22%，技术服务及转让 ...

Core Insights - The article highlights the journey of Yuandong Biopharmaceuticals and its chairman Wang Ying, focusing on the company's resilience and strategic decisions in the pharmaceutical industry [1][2]. Company Overview - Yuandong Biopharmaceuticals has transitioned from a focus on high-end generic drugs to innovative drug development, achieving significant progress in its drug pipeline [2][5]. - The company has successfully industrialized over 70 high-end chemical drugs, including 9 domestic first-generic products and 61 that have passed consistency evaluations [4]. Strategic Decisions - The company initially chose to develop high-end generic drugs to avoid competition in the low-end market, which has proven effective over the years [3]. - Yuandong Biopharmaceuticals has maintained a stable growth trajectory despite industry pressures, with a reported net profit of 137 million yuan in the first half of 2025, showing year-on-year growth after excluding stock incentive costs [3]. Research and Development - Since 2012, the company has invested in R&D, with a focus on innovative drugs, which it views as essential for future growth [5][6]. - The company employs a strategy of "using generics to promote innovation," allowing cash flow from generics to support the development of innovative drugs [7]. Clinical Progress - As of the first half of 2025, the company has made substantial advancements in its innovative drug pipeline, with over 80 projects under research, of which 24.4% are innovative drug projects [7]. - Notable achievements include the completion of clinical trials for several drugs, indicating a shift from initial development to broader market readiness [7]. Future Aspirations - Wang Ying expresses a vision for significant growth in both profits and revenue over the next decade, reflecting the company's long-term strategic goals [8].

苑东生物(688513.SH)艾拉莫德片获得药品注册证书发布公告，公司全资子公司成都硕德药业有限公司 (以下简称"硕德药业")于近日收到国家药品监督管理局(以下简称"国家药监局")核准签发的《药品注册 证书》，涉及药品："艾拉莫德片"。 艾拉莫德片活性成份为艾拉莫德，适应症为活动性类风湿关节炎。艾拉莫德片属于《国家基本医疗保 险、工伤保险和生育保险药品目录(2024年)》乙类品种。 ...

Core Viewpoint - Yuan Dong Biotech (688513.SH) has received a drug registration certificate for Elamomide tablets, indicating a significant regulatory approval for the company’s product aimed at treating active rheumatoid arthritis [1] Group 1: Company Information - The drug Elamomide, developed by the company's wholly-owned subsidiary Chengdu Shuo De Pharmaceutical Co., Ltd., has been approved by the National Medical Products Administration (NMPA) [1] - Elamomide tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2024 [1]

Core Viewpoint - Yuan Dong Biotech (688513) announced the approval of its subsidiary Chengdu Shuo De Pharmaceutical Co., Ltd. for the drug registration certificate of Elamomab tablets by the National Medical Products Administration [1] Company Summary - The active ingredient of Elamomab tablets is Elamomab, which is indicated for the treatment of active rheumatoid arthritis [1] - Elamomab tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024) [1]

Group 1 - The core point of the article is that Chengdu Yuandong Biopharmaceutical Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for its product "Elamomab Tablets" [1] Group 2 - Chengdu Yuandong Biopharmaceutical's wholly-owned subsidiary, Chengdu Shuo De Pharmaceutical Co., Ltd., is responsible for the newly approved product [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) has received approval from the National Medical Products Administration for its drug, Elamomab Tablets, which is indicated for active rheumatoid arthritis and is classified as a Category B drug in the 2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog [1] Group 1 - The company’s wholly-owned subsidiary, Chengdu Shuo De Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Elamomab Tablets [1] - Elamomab, the active ingredient in the tablets, is specifically aimed at treating active rheumatoid arthritis [1] - The drug is included in the 2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog as a Category B product [1]

证券代码：688513 证券简称：苑东生物 公告编号：2025-075 关于自愿披露艾拉莫德片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）全资子公司成都硕德药 业有限公司（以下简称"硕德药业"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的《药品注册证书》，现将相关情况公告如下： 一、药品基本情况 药品名称：艾拉莫德片 剂型：片剂 规格：25mg 注册分类：化学药品 4 类 药品有效期：24 个月 上市许可持有人：成都硕德药业有限公司 成都苑东生物制药股份有限公司 米内网重点省市公立医院数据显示，艾拉莫德片2024年销售金额约38,211万 元，同比增长12.90%。 生产企业：成都硕德药业有限公司 药品注册标准编号：YBH25802025 受理号：CYHS2402863 证书编号：2025S03153 药品批准文号：国药准字 H20255709 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的 ...

Core Insights - The company announced that its wholly-owned subsidiary, Chengdu ShuoDe Pharmaceutical Co., Ltd., received the drug registration certificate for Elamomab tablets from the National Medical Products Administration [1] - Elamomab tablets are indicated for the treatment of active rheumatoid arthritis and are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2024 [1] - The projected sales amount for Elamomab tablets in key public hospitals in major provinces and cities for 2024 is approximately 382 million yuan, representing a year-on-year growth of 12.90% [1] - The approval of this drug is considered equivalent to passing the consistency evaluation, and it is not expected to have a significant impact on the company's recent performance [1]